AVBP ArriVent BioPharma Inc.

Price (delayed)

$33.375

Market cap

$1.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.47

Enterprise value

$1.49B

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize ...

Highlights
The equity has soared by 60% YoY and by 5% from the previous quarter
The EPS has grown by 20% from the previous quarter and by 8% YoY
The net income has declined by 14% year-on-year but it is up by 13% since the previous quarter
ArriVent BioPharma's quick ratio has increased by 8% QoQ but it has decreased by 3.9% YoY

Key stats

What are the main financial stats of AVBP

AVBP stock price

How has the ArriVent BioPharma stock price performed over time
Intraday
12.07%
1 week
23.75%
1 month
9.86%
1 year
46.9%
YTD
65.88%
QTD
44.67%

Financial performance

How have ArriVent BioPharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$156.87M
Net income
-$145.24M
Gross margin
N/A
Net margin
N/A
The net income has declined by 14% year-on-year but it is up by 13% since the previous quarter
ArriVent BioPharma's operating income has decreased by 12% YoY but it has increased by 12% from the previous quarter

Price vs fundamentals

How does AVBP's price correlate with its fundamentals

Growth

What is ArriVent BioPharma's growth rate over time

Valuation

What is ArriVent BioPharma stock price valuation
P/E
N/A
P/B
4.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 20% from the previous quarter and by 8% YoY
The equity has soared by 60% YoY and by 5% from the previous quarter
AVBP's P/B is 45% above its last 4 quarters average of 2.8

Efficiency

How efficient is ArriVent BioPharma business performance
ArriVent BioPharma's ROIC has soared by 56% YoY and by 24% from the previous quarter
ArriVent BioPharma's ROA has increased by 22% from the previous quarter and by 2.8% YoY
ArriVent BioPharma's ROE has increased by 22% from the previous quarter

Dividends

What is AVBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVBP.

Financial health

How did ArriVent BioPharma financials performed over time
The company's total liabilities has surged by 95% YoY but it fell by 2.4% QoQ
ArriVent BioPharma's total assets has soared by 62% YoY and by 4.8% from the previous quarter
AVBP's debt is 100% smaller than its equity
The equity has soared by 60% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.